OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
Study sponsor: Opthea Limited
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-03-31Actual
Enrollment · participants986Actual
Source updated2025-07-22Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.